[quick news] Tuesday, January 30, 2018

Avastin biosimilars have been approved by the European Union Pharmatimes reported on January 22, 2018 that European regulators have approved Amgen and Allergan's mvasi, which is the first biosimilars approved by Roche Avastin in the European Union Mvasi is the first EU approved drug to be jointly marketed by Amgen and Allergan, "highlighting our shared commitment to the success of cancer bio generics," said Nicholson, chief R & D officer of Allergan Pharmatimes http:// sun Lingdong of Peking University is the new deputy editor of nanoscale Recently, nanoscale, a journal of the Royal Society of chemistry, announced that Professor Sun Lingdong, a National Key Laboratory of rare earth materials chemistry and application of Peking University, has become the deputy editor of the journal The editor in chief of nanoscale journal is academician Bai Chunli, President of Chinese Academy of Sciences, researcher Jiang Xingyu, National Center for nanoscience, Professor Xu Hongxing, Wuhan University and Professor Quan Li, Chinese University of Hong Kong RSC http://blogs.rsc.org/nr/2018/01/17/meet-our-new-associate-editors/ 58% of global patents accepted for graphene come from China According to the report released by the patent Committee of China graphene industry technology innovation strategic alliance recently, 58% of global patents accepted for graphene come from China From the perspective of countries of important patent applicants, there are 76 applicants applying for no less than 60 patents, including 8 from the United States, 3 from Japan, 16 from South Korea, and 49 from China, which are in an absolute leading position CCIN http:// European Union approved AstraZeneca fasenra for severe asthma treatment pmlive recently reported that the European Union approved AstraZeneca interleukin-5 (IL-5) inhibitor fasenra for severe asthma The drug was approved in the United States last November Fasenra (benralizumab) is the third IL-5 target drug approved for marketing after mepolizumab and reslizumab According to AstraZeneca, fasenra is the first respiratory biological drug with 8 weeks' administration Pmlive http:// Liping and Jiang Lei of Institute of physics and chemistry of Chinese Academy of Sciences published a cover review in Chem SOC Rev recently, researcher Wen Liping and academician Jiang Lei of Institute of physical and chemical technology of Chinese Academy of Sciences, etc published in Chemical Society Reviews In this paper, the bionic intelligent asymmetric nano channel membrane system (bsanm) has been widely and deeply introduced, and has been selected as the current cover article RSC http://pubs.rsc.org/en/content/articlelanding/2018/cs/c7cs00688h#!divAbstract